American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™'s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™'s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/
Free account • No credit card • 5 profiles/day
The widely used American Gene Technologies® International Inc. email format is {first_initial}{last}@americangene.com (e.g. jsmith@americangene.com), which is used 100% of the time.
| American Gene Technologies® International Inc. Email Formats | Example Email Formats | Adoption |
|---|---|---|
| {first_initial}{last} | jsmith@americangene.com |
100%
|
Adoption = share of company emails using each format — not a verification or accuracy score.
Blue Bee, Inc.
Retail • 2-10 employees • Santa Barbara, United States
DNAnexus
Biotechnology Research • 201-500 employees • Mountain View, United States
VintaBio
Biotechnology Research • 11-50 employees • Philadelphia, United States
Immusoft
Biotechnology Research • 11-50 employees • Seattle, United States
Inceptor Bio
Biotechnology Research • 51-200 employees • Morrisville, United States
GeoVax Labs, Inc.
Biotechnology Research • 11-50 employees • Smyrna, United States
What is American Gene Technologies® International Inc. email format?
The widely used American Gene Technologies® International Inc. email format is {first_initial}{last} (e.g. jsmith@americangene.com) with 100% adoption across the company.
What is American Gene Technologies® International Inc. customer service number?
To contact American Gene Technologies® International Inc. customer service number in your country click here to find.
Who are the decision makers in American Gene Technologies® International Inc.?
The decision makers in American Gene Technologies® International Inc. are Drew Palin, Jeff Galvin, Jeff Galvin, etc. Click to Find American Gene Technologies® International Inc. decision makers emails.
What types of diseases does American Gene Technologies® focus on treating?
American Gene Technologies® specializes in developing gene and cell therapies for a variety of conditions, including infectious diseases, cancers, and monogenic disorders. Their research includes innovative treatments for HIV, Hepatitis-C, and various types of cancer, as well as therapies aimed at autosomal disorders.
How does American Gene Technologies® approach gene therapy?
AGT™ employs cutting-edge gene therapy techniques that involve modifying genes to treat or prevent diseases. This may include delivering therapeutic genes to patients' cells to correct genetic defects or enhance the immune response against cancer. Their approach is rooted in rigorous scientific research and clinical trials to ensure safety and efficacy.
What is the significance of immuno-oncology in AGT™'s research?
Immuno-oncology is a critical area of focus for American Gene Technologies® as it leverages the body's immune system to fight cancer. By developing therapies that enhance immune responses, AGT™ aims to create more effective treatments that can target and destroy cancer cells while minimizing damage to healthy tissues.
Are there any ongoing clinical trials for AGT™'s therapies?
Yes, American Gene Technologies® is actively conducting clinical trials for its gene and cell therapies. These trials are essential for evaluating the safety and effectiveness of their treatments. Interested individuals can find more information about ongoing trials and eligibility criteria on the company’s website or by contacting their clinical research team.
What industries does American Gene Technologies® serve?
AGT™ primarily serves the biotechnology and pharmaceutical industries. Their innovative therapies have the potential to transform treatment options for patients suffering from various diseases, thereby impacting healthcare providers, researchers, and patients alike. The company's work also intersects with academic institutions and research organizations focused on advancing medical science.
How can I stay updated on American Gene Technologies®'s latest developments?
To stay informed about the latest news, research developments, and clinical trial updates from American Gene Technologies®, you can subscribe to their newsletter, follow them on social media platforms, or regularly check their official website. They often publish press releases and updates that provide insights into their ongoing projects and breakthroughs.
